Pelvic inflammatory disease is a risk factor for cervical cancer

The acquisition of human papillomavirus (HPV), the most important etiological agent of cervical cancer, does not cause clinical complaints. Although HPV spreads together with agents causing pelvic inflammatory disease (PID) with complaints forcing the patient to seek medical advice, PID has not yet been evaluated as a predictor of cervical cancer. The present study aimed to determine the relationship between PID and HPV in order to evaluate the possible risk factor role of PID for cervical cancer. Two groups of patients were studied: (i) 2,215 women with PID; (ii) 4,217 women participating in a cervical cancer screening programme who were found to have cytological atypia, mucopurulent cervicitis or other colposcopically detected disorders but were free of symptoms of PID. The presence of HPV and other STD agents in cervical smears was detected with polymerase-chain reaction. HPV prevalence was 33.74% in patients with PID and 26.40% in the group of women without PID (p < 0.001). This suggests that patients suffering from PID apparently have a higher risk of cervical cancer.

Human papillomaviruses; Pelvic inflammatory disease; Cervical cancer; Polymerase chain reaction

[I] World Health Organization: Health for All Dataset, www.who.ch.

[2] Editorial commentary: "The EU's answer to future public-health challenges". Lancet, 359, 2211, 2002.

[3] Cuzick J., Szarewski A., Terry G., Ho L., Hanby A., Maddox P. et al.: "Human papillomavirus testing in primary cervical screening" Lancet, 1995, 345, 1533.

[4] Meijer C.J., Helmerhorst T.J., Rozendaal L., van der Linden J.C., Yoorhorst F.J., Walboomers J.M.: "HPV typing and testing in gynaecological pathology: has the time come?". Histopathology, 1998, 33, 83.

[5] Josefsson A.M., Magnusson P.K., Ylitalo N., Sorensen P., (2warforth-Tubbin P., Andmen _P.K: "Viral load ?f human papiliomavirus 16 as a determinant for development of cervical carcinoma in situ: a nested case-control study". Lancet, 2000, 355, 2189.

[6] Meijer C.J., Rozendaal R., Walboomers J.M.: "Clinical role of HPV testing". In: "Global challenge of cervical cancer screening and prevention". J. Monsonego (ed.). CME J. Gynecol. Oneal., 2000, 5, 14, 26.

[7] Jacobs M.Y., Walboomers J.M., Snijders P.J., Voorhorst F.J., Yerheijen R.H., Fransen-Daalmeijer N., Meijer C.J.: "Distribution of 37 mucosotropic HPV types in women with cytologically normal cervical smears: the age related patterns for high-risk and low-risk types". Int. J. Cancer, 2000, 87, 221.

[8] Report of the US Preventive Services Task Force: "Guide to Chnical Preventive Services". Baltimore, Williams and Wilkins, 1989.

[9] Chiarini F., Pisani S., Gallinelli C., Papi E., Seganti L., Degener A.M. et al.: "Simultaneous detection of HPV and other sexually transmitted agents in chronic urethritis". Minerva Ural. Nephrol., 1998, 50, 225.

[10] Giraud J., Coiffic J., Poulain P., Kerisit J.: "High prevalence of cervical intra-epithelial neoplasia in women treated for pelvic inflammatory disease". Eur. J. Obstet. Gynecol. Reprod. Biol, 1998, 81, 51.

[11] Briggs R.M., Holmes K.K., Kiviat N., Barker E., Eschenbach D.A., De Yong R.: "High prevalence of cervical dysplasia in STD clinic patients warrants routine cytologic screening". Am. J Public. Health., 1980, 70, 1212.

[12] Becker T.M., Wheeler C.M., McGough N.S.: "Sexually transmitted diseases and other risk factors for cervical dysplasia among south-western hispanic and non-hispanic white women". J. Am. Med. Assoc., 1994. 271, 1181.

[13] Kamb M.L.: "Cervical cancer screening of women attending sexually transmitted disease clinics". Clin. Infect. Dis., 1995, 20 (suppl. I), S98.

[14] Boom R., Sol CJ., Salimans M.M., Jansen C.L., Wertheim-van Dillen P.M., van der Noordaa J.: "Rapid and simple method for purification of nucleic ac心”.J. Clin. Microbial., 1990, 28, 495.

[15] Farrell D.J.: "Evaluation of AMPLICOR Neisseria gonorrhoeae PCR using cppB nested PCR and 16S rRNA PCR". J. Clin. Microbiol., 1999, 37, 386.

[16] Catry M.A., Borrego M.J., Cardoso J., Azevedo J., Santo I: "Comparison of the Amplicor Chlamydia trachomatis test and cell culture for the detection of urogenital chlamydia! infections". Genitourin Med., 1995, 71, 247.

[17] Blanchard A., Crabb D.M., Dybvig K., Duffy L.B., Cassell G.H.: "Rapid detection of tetM in Mycoplasma hominis and Ureaplasma urealyticum by PCR: tetM confers resistance to tetracycine but not necessarily to doxycycline". FEMS Microbial. Lett., 1992, 74, 277.

[18] Grodstein F., Tothman K.J.: "Epidemiology of pelvic inflammatory disease". Epidemiology, 1994, 5, 234.

[19] Cox J.T.: "Epidemiology of cervical intra-epithelial neoplasia: the role of human papillomavirus". Clin. Obstet. Gynecol., 1995, 9, 1.

[20] Bornstein J., Rahat M.A., Abramovici H.: "Etiology of cervical cancer: current concepts". Obstet. Gynecol. Surv., 1995, 50, 146.

[21] Duggan M.A.: "Human papillomaviruses in gynecological cancer". Curr. Opin. Obstet. Gynecol., 1996, 8, 56.

[22] Lehtinen M., DilIner J., Knekt P. et al.: "Serologically diagnosed infection with human papillomavirus type 16 and risk for subsequent development of cervical carcinoma". Br. Med. J., 1996, 3/2, 537.

[23] Dillner J., Lehtinen M., Bj0rge T. et al.: " Prospective seroepidemiologic study of human papillomavirus infection as a risk factor for invasive cervical cancer". J. Natl. Cancer Inst., 1997, 89, 1293.

[24] Koskela P., Anttila T., BjOrge T. et al.: "Chlamydia trachomatis infection as a risk for invasive cervical carcinoma". Int. J. Cancer, 2000, 85, 35.

[25] Anttila T., Saikku P., Koskela P. et al.: "Serotypes of Chlamydia trachomatis and risk for development of cervical squamous cell carcinoma". JAMA, 2001, 285, 47.